solnerstotug
Generic: Solnerstotug·Code: SNS-101
solnerstotug: sourced relationships with 1 company · 1 clinical trial tracked.
solnerstotug evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect solnerstotug to FTH; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could solnerstotug → FTH affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Faeth Therapeutics, Inc. (FTH) | Phase 2 |
Clinical Trial Registry Records (1)
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Primary endpoint: Adverse Events - Part A & B
Interventionalopen98 enrolledStarted 2023-05Completion 2026-0610 sites · United StatesSensei Biotherapeutics, Inc.
Frequently asked questions
Which companies have sourced relationships with solnerstotug?
solnerstotug has dated SEC/FDA relationship records for Faeth Therapeutics, Inc..
How many clinical trials involve solnerstotug?
BioSniper tracks 1 clinical trial involving solnerstotug.